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Statistical analysis plan for the ‘Triple Antiplatelets for Reducing Dependency
after Ischaemic Stroke’ (TARDIS) trial
Philip M. W. Bath1*, Katie Robson1, Lisa J. Woodhouse,1 Nikola Sprigg1, Robert Dineen2,
Stuart Pocock3, and on behalf of the TARDIS Trialists
Rationale Antiplatelet agents such as aspirin, clopidogrel and
dipyridamole are effective in reducing the risk of recurrence
after a stroke. Importantly, the risk of recurrence is highest
immediately after the index event while antiplatelets cause
bleeding.
Aims and/or hypothesis The ‘Triple Antiplatelets for Reducing
Dependency after Ischaemic Stroke’ (TARDIS) trial is testing
whether short-term intensive antiplatelet therapy is safe and
effective in reducing the early risk of recurrence as compared
with standard guideline-based therapy.
Design TARDIS is an international multi-center prospective
randomized open-label blinded–end-point trial, with funding
from the UK Health Technology Assessment program. Patients
with acute ischemic stroke or transient ischemic attack are
randomized within 48 h to intensive/triple antiplatelet therapy
or guideline antiplatelets taken for one-month. Patients or
relatives give written informed (proxy) consent and all sites
have research ethics approval. Analyses will be done by
intention-to-treat.
Study Outcome The primary outcome is shift in stroke recur-
rent events and their severity, assessed using the modified
Rankin Scale, at three-months.
Discussion This paper and attachment describe the trial’s sta-
tistical analysis plan, as developed from the protocol during
recruitment and prior to unblinding of data. The statistical
analysis plan contains design and methods for analyses, and
unpopulated tables and figures for the primary and baseline
publications. The data from the trial will provide the first
large-scale randomized evidence for the use of intensive anti-
platelet therapy for preventing recurrence after acute stroke
and transient ischemic attack.
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Stroke and transient ischemic attack (TIA) are complicated by a
high risk of recurrence during the first few hours and days after
the index event; a risk that can be mitigated with early and mul-
timodal prophylaxis (1,2). Two mega-trials demonstrated that
early antiplatelet therapy with aspirin is effective at reducing
recurrence after ischemic stroke (3,4). A meta-analysis of small
trials suggested that dual antiplatelet therapy given within 72 h of
onset was superior to monotherapy in reducing the early risk of
recurrence (5); this systematic review suggested that the compo-
sition of antiplatelets (aspirin, clopidogrel, dipyridamole) was less
important than using two rather than one agent. Subsequently,
the large CHANCE trial found that combined aspirin and clopi-
dogrel was superior to aspirin alone in preventing stroke recur-
rence by 90 days in Chinese patients with minor ischemic stroke
or TIA when randomized within 24 h of onset (6,7).
If dual therapy is superior to monotherapy for acute treatment/
prophylaxis, then intensive/triple antiplatelet therapy (aspirin +
clopidogrel + dipyridamole) might be better still providing the
risk of recurrence is high and bleeding does not become excessive.
A series of ‘proof-of-mechanism’ and ‘proof-of-concept’ studies
have investigated this approach (8–12). In vitro studies found that
triple therapy was most effective in inhibiting platelet aggrega-
tion, platelet–leucocyte conjugation, and leucocyte activation
(8–10). In multiway crossover phase I and II trials comparing
short-term administration of mono, dual and triple antiplatelet
therapy, the combination of aspirin + clopidogrel, with or
without dipyridamole, was most potent in inhibiting platelet
function ex vivo in both normal volunteers and participants with
previous stroke/TIA (11,12). A small parallel group trial of inten-
sive therapy in participants with stroke reported that triple
therapy (vs. aspirin alone) was feasible to administer for up to 24
months (13) although there was a nonsignificant trend to
increased bleeding with intensive treatment. Chronic triple treat-
ment may be useful in clinical practice in participants at very high
risk of recurrence, defined as recurrence on dual antiplatelet
therapy (14).
On the basis of these preclinical and clinical data showing
feasibility, tolerability and apparent safety of intensive/triple anti-
platelets, and the potential for efficacy, the large ‘Triple Antiplate-
lets for Reducing Dependency after Ischaemic Stroke’ (TARDIS)
was started and is ongoing. TARDIS is assessing, in a prospective,
randomized, open-label, blinded-outcome design, the safety and
efficacy of intensive vs. guideline antiplatelet therapy. The trial
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commenced in 2009 and will reach 50% of its planned recruit-
ment of 4,100 patients during 2014. The independent Data Moni-
toring Committee has assessed unblinded data from the trial on
eight occasions to date and, on each occasion, recommended that
TARDIS should continue.
The accompanying Supporting Information Appendix S1
details the statistical analysis plan (SAP) and is published during
recruitment and well before final data cleaning and locking of the
trial database so that analyses are not data driven or selectively
reported (15). As for the ENOS trial (16), this SAP includes not
just information on the planned primary publications but also
provides detailed information on the intended baseline charac-
teristics publication.
TARDIS will be reported as both a prevention trial, i.e. effi-
cacy of intensive antiplatelet agents for reducing the frequency
and severity of recurrent stroke and TIA (primary aim), and an
acute intervention trial, i.e. efficacy in shifting functional
outcome. TARDIS is using a novel primary outcome based on
both the frequency and severity of recurrent strokes. Conven-
tionally, vascular prevention trials just count recurrent events.
However recurrent events may be mild, severe or fatal, and this
information can allow ordered categorical outcomes to be
defined: fatal event/severe event/moderate event/mild event/no
event. Analysis of such polytomous outcomes is more efficient
statistically, i.e. they provide improved statistical power for a
given sample size, or allow a trial to be smaller for a given
power, as shown in an empirical re-analysis of published vascu-
lar prevention trials (17,18). This approach follows that used for
the design and analysis of trials in acute stroke (19,20). Simi-
larly, adjusted analyses provide additional statistical power (21),
are important if minimization is used during the process of ran-
domization (22), and help address any minor imbalances
present at baseline due to chance. As a result, these statistical
approaches are likely to be more sensitive to any treatment effect
and, as such, are recommended by the European Stroke Organi-
sation (23). The use of these approaches, and inclusion of TIA
as part of the spectrum of outcomes, allows the size of TARDIS
to be almost halved from ∼8000 patients. The collection of all
baseline data needed for covariate adjustment of the primary
outcome should mean there is no need for imputation for
missing data.
Guidelines for use of antiplatelet agents after stroke have
changed during the conduct of the trial. At the start of the trial,
the UK National Institute for Health and Clinical Excellence
(NICE) had recommended the use of aspirin and dipyridamole
for secondary prevention (24) and the initial trial protocol
defined this as the guideline comparator. However, the wide-
spread availability of inexpensive generic clopidogrel, and signifi-
cant randomized evidence supporting the use of clopidogrel after
stroke, led NICE to update their earlier guidance in 2010 with a
recommendation that clopidogrel should be used for secondary
prophylaxis. As a result, the protocol was updated and allowed the
use of either combined aspirin and dipyridamole, or clopidogrel
alone, as the comparator. Investigators are allowed to choose
whether randomization includes one or both comparators and
this choice can be made separately for stroke and TIA. Choices
can be changed but not within 48 h so they cannot influence
randomization for a particular patient.
This SAP also informs some of the content of the final trial
report to be submitted to the NIHR Health Technology Appraisal
(HTA) program; the final report will be submitted for publication
in the HTA Journal, part of the NIHR collection of peer-reviewed
open access journals. In the future, data from TARDIS will be
integrated into individual patient data meta-analyses of antiplate-
let agents in acute stroke, and made available to participating
countries, and the ‘Virtual International Stroke Trials Archive’
(VISTA) (25). Ultimately, a subset of the data will be made avail-
able over the web, as with the International Stroke Trial (26).
Similarly, anonymized baseline and on-treatment neuroimaging
data will be published (27).
Supporting information
Additional Supporting Information may be found in the online
version of this article at the publisher’s website.
Appendix S1. Statistical analysis plan (TARDIS).
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